Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
For prescribing by certain health practitioners Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“DILANTIN is an anticonvulsant drug, which can be useful in the treatment of epilepsy.”
“In general the reported plasma half-life of phenytoin averages 22 hours, with a range of 7 to 42 hours.”
“Phenytoin is metabolised in the liver primarily by CYP2C9 (major) and CYP2C19 (minor) (see Section 4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS).”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.